The Cyclin-dependent kinase (CDK) class of serine/threonine kinases has crucial roles in
the regulation of cell cycle transition and is mainly involved in the pathogenesis of cancers …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer
(CRC); however, frequent drug resistance limits its therapeutic efficacy in patients. Here, this …

Glioblastoma multiforme (GBM) is the most lethal primary brain tumor with a poor median
survival of less than 15 months. However, clinical strategies and effective therapies are …

Pancreatic cancer is the third most common cause of cancer-related deaths in the United
States. Although gemcitabine is the standard of care for most patients with pancreatic …

KRAS mutation is the most frequent oncogenic aberration in colorectal cancer (CRC). The
molecular mechanism and clinical implications of KRAS mutation in CRC remain unclear …

Background Inhibition of CDK7, a potent transcription regulator, may bring new hope for
treating pancreatic ductal adenocarcinoma (PDAC), which is featured by large genetic …

Recent research has shown that cyclin dependent kinase 7 (CDK7), cyclin dependent
kinase 9 (CDK9) and cyclin T1 (CCNT1) can assist transcriptional misregulation in cancer …

Pancreatic ductal adenocarcinoma (PDAC) is a significant obstacle to lowering global
cancer deaths. CB-5083, a novel valosin-containing protein (VCP)/p97 inhibitor that disrupts …

Background In the past decades, cancer enigmatical heterogeneity at distinct expression
levels could interpret disparities in therapeutic response and prognosis. It built hindrances to …